Sunday, November 8, 2026

USD/EUR Is 2% Down In The Last 21 Sessions

USD/EUR Is 2% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.52% for the last 21 sessions. At 13:12 EST on Friday, 14 July, USD/EUR (USDEUR) is $0.89.

USD/EUR's yearly highs and lows, it's 0.101% up from its 52-week low and 15.093% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.52%, a negative 0.17%, and a positive 0.34%, respectively.

USD/EUR's highest amplitude of average volatility was 0.52% (last week), 0.39% (last month), and 0.34% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • According to DailyForex on Wednesday, 12 July, "In the Forex market, the spotlight is onthe USD/JPY currency pairas the Japanese Yen continues its multi-day streak of getting stronger, with the Yen the strongest major currency so far today and the US Dollar the weakest.USD/JPY is now trading well below ¥140 which calls into suggests that the former long-term bullish trend is over, as the price has now made what looks like more than just a bearish retracement. "
  • Usd/jpy price analysis: bears pause near 38.2% fibo., US CPI eyed for fresh impetus. According to FXStreet on Wednesday, 12 July, "The crucial US CPI report should influence the USD and provide some meaningful impetus to the USD/JPY pair.", "On the flip side, the 140.00 psychological mark now seems to act as an immediate hurdle, above which a bout of a short-covering move could lift the USD/JPY pair towards the 140.60 area, representing the 50% Fibo. "
  • Usd/jpy extends losing streak as investors see fed’s interest rate peak sooner. According to FXStreet on Wednesday, 12 July, "The USD/JPY pair has continued its losing spell for the fifth trading session on Wednesday. "
  • Usd/jpy technical analysis: all eyes on US inflation figures - 12 July 2023. According to DailyForex on Wednesday, 12 July, "For the second week in a row, the price of the USD/JPY currency pair is exposed to profit-taking sales that pushed it towards the support level 139.32. ", "Forecasts of the US dollar against the Japanese yen today:The downward shift of the US dollar currency pair against the Japanese yen USD/JPY requires stability below the support level of 140.00, which is what is happening now."
  • Usd/jpy plummets to one-month low, closer to mid-139.00s ahead of the crucial US CPI report. According to FXStreet on Wednesday, 12 July, "The USD/JPY pair prolongs its recent sharp retracement slide from the YTD peak - levels just above the 145.00 psychological mark = and continues losing ground for the fifth successive day on Wednesday. ", "The aforementioned fundamental backdrop, meanwhile, suggests that the path of least resistance for the USD/JPY pair remains to the downside. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com